Energy & Environmental Law Adviser
Product Liability & Mass Torts Blog
Employment Law Landscape
Joel M. Wallace works primarily in intellectual property litigation, with significant experience in patent and trademark litigation and non-litigation analyses across a range of industries including pharmaceuticals, medical devices and consumer goods and services. As part of his practice, he regularly prepares Hatch-Waxman Paragraph IV letters, advises clients on patent and regulatory issues, and advocates for clients in litigation, including fact discovery, expert discovery, trial, and appeal. Joel also has experience in post-grant review practice before the PTO, including preparation of petitions for inter partes review.
Prior to joining Schiff Hardin, Joel was an associate in the Chicago office of an international law firm.
Joel also participated in the following patent litigation matters prior to joining Schiff Hardin:
The Center for Biosimilars
Clinical Trials Arena
Schiff Hardin LLP announced today its launch of a Coronavirus Task Force to address the significant business, legal, and economic challenges facing companies as a result of the coronavirus (COVID-19) pandemic.
The U.S. Food and Drug Administration (FDA) issued a final rule last week that broadened the scope of the Biologics Price Competition and Innovation Act (BPCIA) to include large proteins, even those that could have been previously governed by the Hatch-Waxman Act.
The First Circuit handed the generic pharmaceutical industry an early Valentine’s Day treat earlier this month by resuscitating an antitrust suit against Sanofi by direct purchasers of insulin glargine.
Schiff Hardin won an appeal for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., showing a formulation patent claim is invalid and helping generics further develop the “inherent obviousness” case law.
Pfizer’s recent decision not to disclose data about Enbrel’s potential to treat Alzheimer’s disease has caused much debate about drugmakers’ obligations to the public.
Joel represented plaintiffs in a putative class action suit regarding the issuance of immigration detainers against foreign-born U.S. citizens or legal permanent residents without investigation.
As demonstrated by the California Supreme Court's recent Cipro reverse payment decision, Actavis' ʺrule of reasonʺ is not just guiding federal courts anymore.